Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

AZD6234

Stage Phase 3Stale

Sponsor AstraZeneca

Route oral and injection

Sources

registry, as of 2026-09-29Stale

https://clinicaltrials.gov/study/NCT07017179

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 16. Conditions Obesity/Overweight. This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.

ClinicalTrials.gov NCT07017179 protocol and results modules

registry, as of 2026-10-30Stale

https://clinicaltrials.gov/study/NCT07784725

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus. Overall status RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 2500. Conditions Obesity or Overweight. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

ClinicalTrials.gov NCT07784725 protocol and results modules

registry, as of 2026-04-03Stale

https://clinicaltrials.gov/study/NCT06132841

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 104. Conditions Healthy Participants. A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity

ClinicalTrials.gov NCT06132841 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07922330

A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 330. Conditions Obesity; Overweight; Type 2 Diabetes Mellitus. This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.

ClinicalTrials.gov NCT07922330 protocol and results modules

registry, as of 2026-11-02

https://clinicaltrials.gov/study/NCT07911514

A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 60. Conditions Healthy Participants. This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and w

ClinicalTrials.gov NCT07911514 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07013643

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 100. Conditions Healthy Participants. This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with

ClinicalTrials.gov NCT07013643 protocol and results modules

Studies

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Registry NCT07017179

Phase Phase 2

Status Active, not recruiting

Enrollment 16

Start 2025-05-20

Primary completion 2026-10-23

Study completion 2026-10-23

Catalyst Primary completion. 2026-10-23. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

AZD6234 (sub-study 1)

Regimen weekly

Weeks 16

Comparator placebo

Population Obesity/Overweight

Placebo (sub-study 1)

Regimen weekly

Weeks 16

Population Obesity/Overweight

AZD9550(sub-study 2 Cohort A)

Regimen weekly

Weeks 16

Comparator placebo

Population Obesity/Overweight

Placebo (sub-study 2 Cohort A)

Regimen weekly

Weeks 16

Population Obesity/Overweight

AZD6234 in combination with AZD9550 (sub-study 2 Cohort B)

Regimen weekly

Weeks 16

Comparator placebo

Population Obesity/Overweight

Placebo (sub-study 2 Cohort B)

Regimen weekly

Weeks 16

Population Obesity/Overweight

SELENE 1

Registry NCT07784725

Phase Phase 3

Status Recruiting

Enrollment 2500

Start 2026-08-19

Primary completion 2028-08-11

Study completion 2029-05-21

Catalyst Primary completion. 2028-08-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

AZD6234 Dose 1

Regimen once weekly

Weeks 68

Comparator placebo

Population Obesity or Overweight

AZD6234 Dose 2

Regimen once weekly

Weeks 68

Comparator placebo

Population Obesity or Overweight

Placebo

Regimen once weekly

Weeks 68

Population Obesity or Overweight

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Registry NCT06132841

Phase Phase 1

Status Completed

Enrollment 104

Start 2023-11-13

Primary completion 2026-02-03

Study completion 2026-03-07

Catalyst Primary completion. 2026-02-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Population Healthy Participants

Cohort 2

Population Healthy Participants

Cohort 3

Population Healthy Participants

Cohort 4

Population Healthy Participants

SELENE-Asia

Registry NCT07922330

Phase Phase 3

Status Not yet recruiting

Enrollment 330

Start 2027-01-04

Primary completion 2028-09-15

Study completion 2028-09-15

Catalyst Primary completion. 2028-09-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

AZD6234 Higher Target-Dose

Regimen once weekly

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes Mellitus

AZD6234 Lower Target-Dose

Regimen once weekly

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes Mellitus

Placebo

Regimen once weekly

Population Obesity; Overweight; Type 2 Diabetes Mellitus

A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234

Registry NCT07911514

Phase Phase 1

Status Not yet recruiting

Enrollment 60

Start 2026-11-09

Primary completion 2027-05-04

Study completion 2027-05-04

Catalyst Primary completion. 2027-05-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Regimen A

Population Healthy Participants

Regimen B

Population Healthy Participants

Regimen C

Population Healthy Participants

Regimen D

Population Healthy Participants

Regimen E

Population Healthy Participants

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel

Registry NCT07013643

Phase Phase 1

Status Active, not recruiting

Enrollment 100

Start 2025-06-04

Primary completion 2027-07-09

Study completion 2027-07-09

Catalyst Primary completion. 2027-07-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort-1: AZD6234 + EE/LEVO + Acetaminophen (APAP)

Population Healthy Participants

Cohort-2: AZD6234+AZD9550+EE/LEVO+APAP

Population Healthy Participants

Cohort-3: AZD9550 + EE/LEVO + APAP

Population Healthy Participants

Cohort-4: AZD6234+AZD9550+EE/LEVO+APAP

Population Healthy Participants